GSK (LON:GSK) Insider Luke Miels Sells 4,549 Shares of Stock

GSK plc (LON:GSK) insider Luke Miels sold 4,549 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of GBX 2,211, for a total transaction of £100,578.39.

GSK Price Performance

Shares of LON GSK opened at GBX 2,150 on Thursday. GSK plc has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,219. The company has a market cap of £86.75 billion, a PE ratio of 16.17, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The business’s 50 day moving average price is GBX 1,867.42 and its two-hundred day moving average price is GBX 1,685.32. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, analysts predict that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research report on Wednesday, January 7th. UBS Group restated a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft lifted their price objective on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research note on Thursday, January 15th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Finally, Citigroup lifted their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.